Abstract
We used DNA chip technology in a genetically engineered mouse model of prostate cancer, and identified lumican as a candidate biomarker in prostate cancer progression. Lumican is a small leucine-rich extracellular matrix protein that has been shown to modulate cell migration and proliferation during embryonic development, and tissue repair. Expression and distinct glycosylation patterns of lumican in several tumor and stromal tissues has been shown to play important roles in vascular invasion, differentiation, proliferation, and invasion. Our goal was to determine the clinical value of lumican as a biomarker for human prostate cancer. In order to do so, we examined gene expression in publicly available databases and confirmed the protein expression in tissue microarrays constructed from prostatectomy cases. Protein expression was examined by immunohistochemistry and expression scores were compared with clinicopathological features and disease progression. Our analysis shows that in human prostate cancer, stromal expression of lumican correlated inversely with clinicopathological features associated with disease progression. In addition, biochemical recurrence was significantly longer for patients with high expression of stromal lumican. Our findings suggest that lumican may be a strong candidate prognostic biomarker and warrants prospective validation.
Citation Format: Marco A. De Velasco, Yuji Hatanaka, Takashi Oki, Yurie Kura, Yutaka Yamamoto, Kazuhiro Yoshimura, Nobutaka Shimizu, Masahiro Nozawa, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura. Expression of lumican is negatively associated with the risk of biochemical recurrence in human prostate cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4729. doi:10.1158/1538-7445.AM2014-4729